AKT1 and breast cancer: Conversely, high-MNAI BC cell lines demonstrated reduced sensitivity (or relative resistance) to endocrine therapy (tamoxifen) and targeted agents acting on the AKT–mTOR signaling axis (AKT1/2 and mTOR inhibitors) (Figure 4D–F, Table S7).